TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05484024
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor
Study: NCT05245656
Drug: RB
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Every 4 weeks for 6 cycles~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2
Study: NCT04814511
Drug: Driponin 3 mg Tabletten
Normalized name: Oridonin
DrugBank: Oridonin (DB19086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Driponin 3 mg Tabletten are approved for the treatment of scabies, containing ivermectin as the active ingredient. Driponin is used as a supplementary, peroral add-on combination treatment in addition to topical permethrin therapy and is used exclusively in the second treatment cycle (escalation therapy).
Study: NCT05494060
Drug: Anlotinib hydrochloride capsule
Normalized name: loperamide hydrochloride Oral Capsule
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；
Study: NCT05494060
Drug: Penpulimab Injection
Normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penpulimab Injection 100mg per bottle, 200mg IV Day 1, cycled every 21 days
Study: NCT05300555
Drug: Rivaroxaban 20 MG Oral Tablet
Normalized name: rivaroxaban 20 MG Oral Tablet
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After randomization, the patient will start medication (rivaroxaban 20mg per day or 15mg per day if eGFR between 30 and 50ml/min/1,73m²) within 24 hours. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
Study: NCT05300555
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After randomization, the patient will start medication within 24 hours. Bridge with heparin or enoxaparin is recommended. The INR target is between 2,0 and 3,0. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
Study: NCT05599360
Drug: Vyxeos
Normalized name: Vyxeos
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vyxeos (daunorubicin and cytarabine) liposome for injection
Study: NCT05599360
Drug: Mylotarg
Normalized name: Mylotarg
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of the CD33-directed monoclonal antibody (hP67.6; recombinant humanized immunoglobulin \[Ig\] G4, kappa antibody produced by mammalian cell culture in non-secreting 0 (NS0) cells) that is covalently linked to the cytotoxic agent N-acetyl gamma calicheamicin. Gemtuzumab ozogamicin consists of conjugated and unconjugated gemtuzumab. The conjugated molecules differ in the number of activated calicheamicin derivative moieties attached to gemtuzumab. The number of conjugated calicheamicin derivatives per gemtuzumab molecule ranges from predominantly zero to 6, with an average of 2 to 3 moles of calicheamicin derivative per mole of gemtuzumab.
Study: NCT04856904
Drug: Trifarotene Cream
Normalized name: trifarotene
DrugBank: Trifarotene (DB12808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream to the face once daily, in the evening for 24 weeks
Study: NCT04856904
Drug: Trifarotene Vehicle Cream
Normalized name: trifarotene
DrugBank: Trifarotene (DB12808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will apply a thin a layer of trifarotene vehicle cream to the face once daily, in the evening for 24 weeks
Study: NCT06448572
Drug: EXL01
Normalized name: Elexacaftor
DrugBank: Elexacaftor (DB15444)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 capsule / day
Study: NCT04964414
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nasal irrigation with liquid steroid
Study: NCT05821751
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
Study: NCT05821751
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
Study: NCT06087211
Drug: Duloxetine and magnesium sulphate
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: this group will receive Duloxetine 30 mg orally and an intravenous (IV) infusion of magnesium sulphate 50mg/kg mixed with 200ml normal saline (NS) 1 hour before surgery
Study: NCT06087211
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: this group will receive Duloxetine 30 mg orally and 200ml NS infusion 1 hour before surgery
Study: NCT05238883
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered tislelizumab as described in the experimental arm.
Study: NCT04965532
Drug: sevoflurane anesthesia
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane enhances the effects of rocuronium and significantly prolongs the duration of action of rocuronium and the time to recovery.
Study: NCT04965532
Drug: Propofol Injection
Normalized name: propofol Injection
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol is most commonly used for intravenous anesthesia. In contrast to sevoflurane, propofol has no effects on rocuronium.
Study: NCT04730947
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg orally once a day
Study: NCT05372003
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dupilumab injections will be prescribed and managed by dermatology as standard of care
Study: NCT06050954
Drug: Pembrolizumab (200mg)
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg Pembrolizumab every six weeks via IV infusion.
Study: NCT06050954
Drug: Pembrolizumab (400mg)
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400mg Pembrolizumab every six weeks via IV infusion.
Study: NCT05153174
Drug: Sulforaphane
Normalized name: Sulforaphane
DrugBank: Sulforaphane (DB12422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an over-the counter nutritional supplement. Participants will be given the extra strength tablets.
Study: NCT06454292
Drug: Oliceridine Fumarate
Normalized name: Oliceridine Fumarate
DrugBank: Oliceridine (DB14881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After subjects were enrolled, the original sedative and analgesic drugs were discontinued, and a starting dose of 6ug/kg/h of oliceridine fumarate was continuously pumped, and the time of oliceridine fumarate initiation was recorded as T0. Subjects were assessed for sedation using the RASS score, and for analgesia using the CPOT score. Waiting for the original sedative-analgesic drug to elute until CPOT ≥ 3 and RASS \> 0. Adjust the infusion rate of oliceridine fumarate according to the CPOT score (recommended to be adjusted by 2ug/kg/h, the range of adjustment is 2-20 ug /kg/h, and the maximum infusion rate is not more than 20 ug /kg/h) until the analgesic score of the subject is CPOT\<3. The interval between two trial drug rate adjustments should be ≧5 min, and a CPOT score should be performed before each drug adjustment.
Study: NCT06500286
Drug: Marcaine
Normalized name: Marcaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dorsal penil block 0.25% bupivacaine was administered at a dose of 0.2 ml/k
Study: NCT05119933
Drug: YL-15293
Normalized name: dibenzothiazol-2-yl disulfide
DrugBank: 2,2'-Dibenzothiazyl disulfide (DB14201)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a screening period of approximately 28 days, eligible patients will receive oral YL-15293 once daily until documented disease progression, unacceptable AEs, intercurrent illness prevents further administrations of study treatment, investigator's decision to withdraw the patient, the patient withdraws consent, pregnancy of the patient, or for administrative reasons (see Section 7.1). Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
Study: NCT06306846
Drug: cetuximab+immunochemotharpy
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PD-1 monoclonal antibody and TP chemotheapy combined with cetuximab
Study: NCT05029960
Drug: Brivaracetam
Normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose of 50 mg twice daily for 6 months
Study: NCT00215813
Drug: Poly I: Poly C12U (Rintatolimod)
DrugBank: Rintatolimod (DB16425)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-400 mg IV infusions given twice weekly over a period of 30-60 minutes
Study: NCT00001036
Drug: Thymalfasin
Normalized name: Thymalfasin
DrugBank: Thymalfasin (DB04900)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00001036
Drug: Interleukin-2, Polyethylene Glycolated
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00001036
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04294836
Drug: Curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCM-95® (CURCUGREEN®) is a 100 percent pure extract of turmeric with enhanced bio-availability and bio-efficacy. Its powerful health-promoting benefits are derived from the colorful and aromatic qualities of the Indian spice
Study: NCT05878951
Drug: OnabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intra-detrusor OnabotulinumtoxinA is commonly known as botox
Study: NCT05978609
Drug: Candonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candonilimab 10mg/kg, Ivgtt，Q3W，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
Study: NCT05978609
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin，25mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
Study: NCT05978609
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine 1000mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
Study: NCT05577923
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg loading dose IV, then 6 mg/kg IV, every 3 weeks
Study: NCT05577923
Drug: pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib 320mg, PO daily, continuously
Study: NCT05577923
Drug: Dalpiciclib
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks
Study: NCT05577923
Drug: fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant will be given intramuscle at the dose of 500 mg every 4 weeks (with an additional 500 mg dose given two weeks after the initial dose.
Study: NCT04855266
Drug: Sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg/kg of intravenous iron sucrose (maximum dose of 200 mg). Iron sucrose will be diluted
Study: NCT04984577
Drug: Compound Edaravone Injection-Low dose
Normalized name: edaravone Injection
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Compound Edaravone Injection 30mg/dose (Edaravone 30mg, Taurine 600 mg), one dose every 12 hours, continue for 14 days
Study: NCT04984577
Drug: Compound Edaravone Injection-High dose
Normalized name: edaravone Injection
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Compound Edaravone Injection 50mg/dose (Edaravone 50mg, Taurine 1000 mg), one dose every 12 hours, continue for 14 days
Study: NCT04984577
Drug: Edaravone Injection
Normalized name: edaravone Injection
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Edaravone Injection 30mg/dose, one dose every 12 hours, continue for 14 days
Study: NCT05356403
Drug: Difelikefalin 1 mg Oral Tablet
Normalized name: DIFELIKEFALIN
DrugBank: Difelikefalin (DB11938)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Difelikefalin 1 mg medication taken orally 1 time/day
Study: NCT05062486
Drug: Resveratrol, Quercetin, Curcumin (RQC)
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg resveratrol, 120 mg quercetin, 1000 mg curcumin BID
Study: NCT05062486
Drug: Curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg curcumin BID
Study: NCT05417087
Drug: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
Normalized name: Vortioxetine Hydrobromide
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg equivalent to 20 mg of Vortioxetine
Study: NCT05417087
Drug: Vortioxetine Hydrobromide Tablets
Normalized name: Vortioxetine Hydrobromide
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vortioxetine Hydrobromide Tablets 20mg
Study: NCT05302843
Drug: BPI-28592
Normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Characterize the pharmacokinetics (PK)，safety，antitumor activity of BPI-28592
Study: NCT04759339
Drug: AG-920
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-920 is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%
Study: NCT04925180
Drug: Cyproterone Acetate (Androcur, BAY94-8367)
Normalized name: cyproterone
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed by the treating physician
Study: NCT05128734
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomidewill be administered orally for 7 days (D) every 21 days until progression of the disease in both arms.
Study: NCT05128734
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib will be administered orally twice daily in treatment arm 2.
Study: NCT05815290
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab 10mg/kg iv on day 1 for every 21 days with a total of 8 cycles
Study: NCT05152459
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05152459
Drug: Umbralisib
Normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04642261
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 10mg daily
Study: NCT06385756
Drug: Amobarbital
Normalized name: Amobarbital
DrugBank: Amobarbital (DB01351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants with gynecological laparoscopic surgery who met the trial inclusion criteria were randomly divided into 2 groups. After entering the room, peripheral intravenous infusion was opened and oxygen was absorbed by the mask for 5 L/min. Mean arterial pressure, heart rate and oxygen saturation were routinely monitored. After positioning, the amobarbital-propofol group was given amobarbital sodium 1 mg/kg 1 min before induction, followed by Sufentanil 0.5ug /kg, cisatracurium 0.2mg /kg, penehyclidine hydrochloride 0.01mg /kg, propofol 1.5mg /kg for general anesthesia induction. The propofol group was given the same volume of normal saline 1 min before anesthesia induction, followed by Sufentanil 0.5ug /kg, cisatracurium 0.2mg /kg, penehyclidine hydrochloride 0.01mg /kg, propofol 2.5mg /kg.
Study: NCT06385756
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol
Study: NCT05660395
Drug: Loncastuximab Tesirine
Normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT06435923
Drug: [14C]-darigabat
DrugBank: Darigabat (DB18966)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT04630652
Drug: Risankizumab-Rzaa
Normalized name: risankizumab-rzaa
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risankizumab at a dose of 150 mg with injections administered at baseline, week 4 and week 16 following FDA-approved dosage and time periods
Study: NCT04886453
Drug: Balanced general anesthesia without morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced general anesthesia without morphine
Study: NCT04886453
Drug: Standard general anesthesia balanced with morphine
Normalized name: barbiturates for general anesthesia, in combination with other drugs
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard general anesthesia balanced with morphine
Study: NCT05549024
Drug: 68Ga-RM26-RGD
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
Study: NCT05549024
Drug: 18F-FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18F-FDG injection
Study: NCT05549024
Drug: 68Ga-RM26
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
Study: NCT05549024
Drug: 68Ga-RGD
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
Study: NCT06307093
Drug: RPH-075
Normalized name: RPH-104
DrugBank: Goflikicept (DB16396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)
Study: NCT00000988
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05126836
Drug: Cilostazol 100Mg Tab
Normalized name: CILOSTAZOL 100MG TAB
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol Twice a Day
Study: NCT04885413
Drug: Niraparib in Combination With Anti-PD1 Antibody
Normalized name: Anti-PD1 / CTLA4 Bispecific Antibody XmAb20717
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sintilimab： 200mg i.v., d1, 21days one cycle Niraparib： 200mg p.o qd，d1-d21, 21days one cycle
Study: NCT05868837
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 1000 mg IV on RCP days 1 and 15
Study: NCT04942054
Drug: Part 2
Normalized name: Echinacea Root/Echinacea, Aerial Part 250 MG-250 MG Oral Capsule
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacodyanamic (PD) dose exploration cohorts
Study: NCT04942054
Drug: Part 3
Normalized name: insulin degludec 70 UNT/ML / insulin aspart 30 UNT/ML in 3 ML Pen Injector
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose expansion at dose(s) ≤ maximum tolerated dose (MTD) cohort
Study: NCT06519370
Drug: FDA018-ADC
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive FDA018-ADC 10 mg/kg of body weight via intravenous(IV) infusion on Day1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
Study: NCT06519370
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1.4mg/m\^2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle
Study: NCT05984602
Drug: Canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 250 mg subcutaneous injection in prefilled syringes on day 1 of every 28-day cycle
Study: NCT05984602
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg in a liquid vial (concentrate for intravenous (i.v.) solution) on day 1 of every 28-day cycle
Study: NCT06519370
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 to 1200 mg/m\^2 will be administered IV on day 1 and Day 8 of each 21 day cycle
Study: NCT06519370
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m\^2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle
Study: NCT05984602
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle
Study: NCT05984602
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle